Prospective parents now access services that screen embryos for thousands of disease risks and predict genetic traits like intelligence and athletic ability. Companies offering polygenic risk scoring, which evaluates multiple genetic variants simultaneously, market these tests as tools for preventing serious illness. The technology, however, outpaces regulation and raises ethical questions that experts increasingly flag.
Geneticists and bioethicists worry the science conflates correlation with causation. A genetic predisposition toward a condition does not guarantee disease development. Environmental factors, lifestyle choices, and gene interactions shape outcomes unpredictably. Intelligence predictions prove especially contentious. Polygenic scores explain only a fraction of intelligence variation, yet marketing materials often overstate their predictive power.
The regulatory landscape remains sparse. The FDA has not established clear guidelines for embryo screening beyond aneuploidy detection, the oldest and most reliable form of genetic testing. Companies operate in gray zones, offering direct-to-consumer tests with minimal oversight. No standards exist for how these tests are conducted, what claims can be made, or how results must be communicated.
Class implications intensify the debate. These services cost thousands of dollars per cycle, accessible primarily to wealthy families. Widespread adoption could deepen genetic stratification, where advantaged families select for predicted traits while others cannot. Disability advocates note that reducing selection based on disease risk conflates disability with suffering, potentially narrowing what kinds of human variation society accepts.
Medical societies including the American College of Obstetricians and Gynecologists urge caution. They recommend restricting embryo selection to preventing serious, high-penetrance conditions rather than optimizing traits. The gap between what science can measure and what experts recommend families actually do continues widening as commercial interests expand.
THE BOTTOM LINE: Polygenic screening outpaces scientific evidence and ethical consensus, creating inequality while overpromising genetic destiny.